Prof. Peter Lin

Following graduation from Peking University School of Medicine, and Chinese Academy of Medical Science/Peking Union Medical College (MD), Dr. Peter Lin continued his study in Drs. Carolyn Mold and Terry DuClos lab at the University of New Mexico School of Medicine in U.S.. After obtained his PhD (Immunology) at UNM, Dr. Lin pursued his postdoc training in the lab of Drs. Marilyn Farquhar (former President of American Society for Cell Biology) and George Palade (Nobel Laurite, Cell Biology) at University of California San Diego (UCSD) School of Medicine, where Dr. Lin helped establish a research team for Calnuc study. Collaborating with Dr. Roger Tsien (Nobel Laurite) at UCSD, Drs. Lin and Farquhars’ team made a significant achievement on Calnuc in the fields of tumor cell biology, endocrinology and neuroscience.  

From 2005, Dr. Lin has led a team working on CTC related technology innovation, clinical validation and relative clinical studies. The novel cutting-edge technology of the integrated subtraction enrichment and immunostaining-FISH (SE-i•FISH), invented by Dr. Lin’s team at Cytelligen (San Diego, CA, USA), has exhibited its unique advantage for efficient isolation, in situ phenotypic and karyotypic characterization as well as classification of distinguished viable and necrotic non-hematopoietic circulating aneuploid rare cells based upon degrees of aneuploidy, tumor marker expression, cell morphology and cell viability. Following demonstration of the existence of CD31⁺ aneuploid circulating tumor endothelial cells (CTECs) for the first time by Dr. Lin’s team and collaborators, subcategorized CD31^- CTCs and CD31⁺ CTECs  have been confirmed to possess distinct clinical significance in terms of therapeutic drug resistance, tumor metastasis and recurrence. Our most recently developed biphasic iFISH tumor tissue and liquid biopsies enable comprehensively molecular profiling of tumor cells (TCs), tumor endothelial cells (TECs), CTCs and CTECs, ultimately assisting to illustrate their metastatic relevance, improving risk stratification and clinical management of cancer patients.